ArticleDiagnostic pathology2026
Case report: a case of primary cutaneous diffuse large B-cell lymphoma, leg type with TdT positive in an elderly woman.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPrimary cutaneous diffuse large B-cell lymphoma, leg type(PCDLBCL-LT) is a rare form of lymphoma that originates from the post-germinal center and typically does not express terminal deoxynucleotidyl transferase(TdT), a marker of immunophenotypic immaturity. CASE DESCRIPTION: A 73-year-old female presented to our hospital with recurrent nodules on her lower limbs, which had persisted for over five years without systemic involvement, accompanied by a gradual increase in TdT expression. Histology revealed diffuse infiltration of centroblasts and/or immunoblasts within the dermis and subcutis, with CD20, CD10, BCL2 and c-MYC expression. Fluorescence in situ hybridization (FISH) showed MYC rearrangement without BCL2/BCL6 alterations, corroborating the diagnosis of TdT-positive PCDLBCL-LT. Following six cycle of R-CHOP chemotherapy, the patient achieved complete remission. A follow-up conducted one year showed no tumor recurrence.
conclusionOur case showed that TdT can be expressed in PCDLBCL-LT, and highlight the importance of a comprehensive analysis of clinicopathology and ancillary testing to avoid misdiagnosis. Additionally, the clinical course of TdT-positive PCDLBCL-LT seems remain relatively favorable. However, further research is still needed on this relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.